HOME >> MEDICINE >> NEWS
Maxim Phase II Clinical Trial Highlights Substantial Increase In Leukemia-FreeSurvival For Acute Myelogenous Leukemia Patients

an time in remission before relapse is only 12 months with current treatments.

Relapsed patients are typically treated again with chemotherapy, and many of these patients die during chemotherapy. Among those relapsed patients who do survive treatment and achieve a second complete remission ("CR2"), these subsequent remissions normally have a shorter duration than the prior CR (a median of only 6 months in the case of CR2 patients).

The objective of Maxamine Therapy is to treat AML patients in remission with the combination of Maxamine and low doses of interleukin-2 (IL-2) to prevent relapse and prolong leukemia-free survival while maintaining a good quality of life for the patients during treatment.

Maxamine Improvement in Leukemia-Free Survival

In the ongoing Phase II study, patients treated in their first remission with Maxamine Therapy have experienced a substantial increase in leukemia-free survival, highlighted by the following updated clinical results as of September 1, 1998:

58% (15 of 26) of all CR1 patients treated with Maxamine remained in leukemia-free remission. A prior study (Swansbury, et. al.) of AML patients suggest that 20-25% of patients would be expected to be alive after two years.

65% (13 of 20) AML patients without concurrent disease or antecedent illnesses treated with Maxamine remain in leukemia-free remission.

After a median of 24 months of follow up, the median time to relapse has not been reached in this study as more than 50% of the Maxamine-treated CR1 patients remain leukemia-free. By contrast, under the normal course for AML, the median time to relapse would be expected to be reached after only 12 months.

These results were achieved despite the fact that the patients treated with Maxamine were an older group of patients and more than half (15 of 26) of the patients were categorized as high risk.

"The updated results are very promising," said Dr. Bengt Simonsson, Head of the Division of Haemat
'"/>

Contact: Amy Flood
a.flood@noonanrusso.com
415-677-4455 x211
Noonan/Russo Communications
7-Dec-1998


Page: 1 2 3 4 5 6

Related medicine news :

1. Elan and Biogen Idec announce results from Phase III maintenance trial of Antegren
2. Phase II trial of anthrax vaccine to begin
3. NIAID Phase III HIV vaccine trial to determine correlates of protection will not proceed
4. MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
5. Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy
6. Penn researchers announce results of Phase I trial using combretastatin drug
7. Anti-cocaine vaccine produces antibodies and is shown to be safe in Phase 1 study conducted by Yale researcher
8. Results of NUVANCE (IL-4 receptor) in Phase I/II study in asthma patients featured at AAAAI Late-Breaker Abstract and Asthma Therapy Sessions
9. ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia
10. Abgenix Reports Positive Survival Data From A Phase II Trial Of ABX-CBL In Graft Versus Host Disease
11. Immunex Advances CD40 Ligand To Phase II Clinical Trial In People With Metastatic Kidney Cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/19/2019)... , ... February 19, 2019 , ... Hospice of Westchester ... Foundation. The funds will support the heart of its operation, the organization’s Home Care ... many years, and we are grateful for their ongoing generosity,” said Mary K. Spengler, ...
(Date:2/19/2019)... , ... February 19, 2019 , ... ... needs to improve care outcomes and patient experiences. Through the End2End solution, ... and audiences in key areas: , 1. Access Manager enhances engagement through ...
(Date:2/19/2019)... , ... February 19, 2019 , ... ... dedicated to serving the entire family with modern, state-of-the-art dental treatments in a ... award-winning cosmetic dentist. While Dr. Roberts is known for providing advanced services in ...
(Date:2/19/2019)... ... February 19, 2019 , ... Reproductive Biology Associates ... United States and a part of the Prelude Fertility (Prelude) network, ... Piedmont Atlanta Hospital. , The only reproductive endocrinology practice on the Piedmont Atlanta ...
(Date:2/19/2019)... ... February 18, 2019 , ... AdventHealth Connerton is ... Solutions Footwear Sanitizing Stations to maximize infection control for patients and their families. ... as MRSA and C. difficile, which can be transmitted from the bottoms of ...
Breaking Medicine News(10 mins):
(Date:2/19/2019)... TORONTO (PRWEB) , ... February 18, 2019 , ... ... more about preconception health, assisted reproduction technologies, the benefits of egg freezing, and ... reproductive endocrinologist and Shady Grove Fertility Canada Program Director, Joseph Doyle, M.D. ...
(Date:2/16/2019)... PHILADELPHIA (PRWEB) , ... February 15, 2019 , ... ... focused on dramatically reducing the amount of radiation exposure during fluoroscopically guided procedures, ... management team as Executive Vice President and President of the Mobile C-arm business. ...
(Date:2/16/2019)... Calif. (PRWEB) , ... February 15, 2019 , ... ... protocol gum disease treatment and LAPIP™ protocol for ailing dental implants to the ... him part of a growing population of dentists looking to provide their patients ...
Breaking Medicine Technology:
Cached News: